In conclusion, we have now been able to confirm our previous results, that Wnt5a can be used as a predictive biomarker in PCa patients, which supports a view that Wnt5a is a future therapeutic target in patients with PCa cells displaying low endogenous expression of Wnt5a. Here, WNT5A is linked to posterior cortical atrophy.